[ad_1]
UK pharmaceutical giant AstraZeneca (AZ) has admitted that its Covid vaccine, sold under the brand name Covishield in India, was linked to blood clots in ‘very rare cases’, according to court documents being cited in the UK. May cause side effects. Media. The admission was made in a legal document submitted to the High Court in London in February for a group action by 51 claimants, according to media reports. (Also read: AstraZeneca admits in court that its Covid vaccine may cause rare side effect ‘TTS’, what is it?)
The pharmaceutical company has admitted that the vaccine developed with the University of Oxford to protect against COVID-19 can cause thrombosis with thrombocytopenia syndrome (TTS).
“It is believed that the AZ vaccine may, in very rare cases, cause TTS. The causal mechanism is not known. Additionally, TTS can occur even in the absence of the AZ vaccine (or any vaccine). The reason in any individual case will be the subject of expert evidence,” the Daily Telegraph quoted the legal document as saying.
What is thrombosis with thrombocytopenia syndrome?
“Vaccine-induced thrombosis with thrombocytopenia syndrome (TTS) is an extreme immunological response that occurs following COVID-19 vaccination. It was initially thought to be associated with viral-vector-based vaccines such as Johnson & Johnson/Janssen and AstraZeneca-Oxford “But it was found that the side effect of Covishield vaccine may be activation of platelets and coagulation system and may lead to secondary bleeding in some circumstances,” said Dr. Visvesvaran B. , Consultant Interventional Pulmonology and Sleep Medicine, Yashoda Hospitals Hyderabad.
“The discovery of thrombosis with thrombocytopenia syndrome (TTS), an uncommon but notable adverse event that may be associated with Covishield vaccine, has opened a new chapter regarding COVID-19 vaccination. As a cardiologist today , I try to understand the complexities of cardiovascular health, which requires precise and thorough investigation of this issue, I aim to clarify the foundations of TTS, its clinical implications and the important role of vigilant monitoring in the vaccination scenario Have to do,” says Dr Vanita Arora, senior consultant cardiac electrophysiologist and interventional cardiologist at Apollo Hospitals, Delhi.
symptoms of tts
Dr. Visweswaran says the incidence of TTS among vaccine recipients also appears to be higher among younger individuals and first dose recipients and can manifest as clots and sometimes bleeding in unusual locations. “Persistent and progressively worsening headache in addition to focal neurological symptoms such as visual disturbances have been described as early red flags to suspect VITT in patients,” the experts say.
Elaborating on the symptoms, Dr Visweswaran says, “Most of these patients develop thrombosis in the lower extremities and lungs, but also in the splenic, portal or mesenteric, adrenal, cerebral and even ophthalmic veins.” Clots can also develop in unusual locations, including the blood vessels that supply the stomach.”
“We are seeing that a lot of people are coming in with complications of Covid and especially with complications of Covishield vaccination. We have seen many case reports and cases in our institute, that a lot of patients are having stroke. And cardiovascular complications developed such as arrhythmias and cardiac arrest and failure and also diabetes. One of these complications is thrombosis, which states that blood clots form in the blood vessels of people’s vital organs. Symptoms include severe headache, stroke and abdominal pain, swelling in legs and severe breathlessness, says Dr Gopi Krishna Yedlapati, senior consultant interventional pulmonologist, Yashoda Hospitals Hyderabad. “
Diagnosis of TTS
Dr Vanita Arora says that from a clinical point of view, diagnosing TTS is very challenging and requires a high level of suspicion and sharp clinical judgment, especially in people who received the Covishield vaccine Is.
“Patients may experience a broad spectrum of symptoms, ranging from severe headache and characteristic neurological deficits to more subtle signs of a thrombotic episode. However, the co-occurrence of thrombosis and thrombocytopenia differentiates TTS and is of interest to medical practitioners. Emphasizes the diagnostic puzzle. The differential diagnosis should include a wide range of thrombotic and thrombocytopenic disorders, requiring comprehensive evaluation and careful diagnostic modalities, including imaging tests and hematological evaluation. Requires application.”
How can it be treated
“When treating patients with TTS, cardiologists need to carefully consider the risks of thrombosis and bleeding issues. To reduce the burden of thrombosis, anticoagulation is still necessary, but each patient has specific risks. Only after a thorough assessment of the profile and supporting documentation to learn more about the effects of adjuvant medications, including intravenous immunoglobulin, platelet transfusions and corticosteroids, on the immune response associated with the pathophysiology of TTS, a Patients require interdisciplinary collaboration between cardiologists, hematologists, neurologists and other allied health specialists,” says Dr Arora.
[ad_2]
